Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gruben

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Statistics in Medicine|June 30, 2011
A case study of model-based Bayesian dose response estimationHuaming Tan, David Gruben, Jonathan French, et al.
Advances in Therapy|February 8, 2021
Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey AnalysisShawn G Kwatra, David Gruben, Selwyn Fung, et al.
Clinical Therapeutics|October 19, 2016
Corrigendum to "Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases" Clin Ther 38 (2016) 1451-63James Harnett, Jeffrey R Curtis, Robert Gerber, et al.
Lancet (London, England)|May 28, 2013
Tofacitinib for rheumatoid arthritis - Authors' replyGerd R Burmester, Birgitta Benda, David Gruben, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims DatabaseJames Harnett, Robert Gerber, David Gruben, et al.
Clinical Therapeutics|April 27, 2016
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims DatabasesJames Harnett, Jeffrey R Curtis, Robert Gerber, et al.
Journal of Managed Care & Specialty Pharmacy|March 23, 2016
Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic DrugsJames Harnett, Daniel Wiederkehr, Robert Gerber, et al.
Advances in Therapy|April 28, 2022
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims DatabasePhilip J Mease, Pamela Young, David Gruben, et al.
Dermatology and Therapy|April 6, 2022
Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USAArash Mostaghimi, Jason Xenakis, Aster Meche, et al.
Rheumatology and Therapy|January 23, 2023
High Usability and Applicability Ratings for the New SmartClic<sup>®</sup>/ClicWise<sup>®</sup> Injection Device: Evidence from a Health Care Professional Opinion StudyRieke Alten, Simon Moss, Stefanie Hahne, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Statistics in Medicine|June 30, 2011
A case study of model-based Bayesian dose response estimationHuaming Tan, David Gruben, Jonathan French, et al.
Advances in Therapy|February 8, 2021
Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey AnalysisShawn G Kwatra, David Gruben, Selwyn Fung, et al.
Clinical Therapeutics|October 19, 2016
Corrigendum to "Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases" Clin Ther 38 (2016) 1451-63James Harnett, Jeffrey R Curtis, Robert Gerber, et al.
Lancet (London, England)|May 28, 2013
Tofacitinib for rheumatoid arthritis - Authors' replyGerd R Burmester, Birgitta Benda, David Gruben, et al.
Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims DatabaseJames Harnett, Robert Gerber, David Gruben, et al.
Clinical Therapeutics|April 27, 2016
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims DatabasesJames Harnett, Jeffrey R Curtis, Robert Gerber, et al.
Journal of Managed Care & Specialty Pharmacy|March 23, 2016
Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic DrugsJames Harnett, Daniel Wiederkehr, Robert Gerber, et al.
Advances in Therapy|April 28, 2022
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims DatabasePhilip J Mease, Pamela Young, David Gruben, et al.
Dermatology and Therapy|April 6, 2022
Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USAArash Mostaghimi, Jason Xenakis, Aster Meche, et al.
Rheumatology and Therapy|January 23, 2023
High Usability and Applicability Ratings for the New SmartClic<sup>®</sup>/ClicWise<sup>®</sup> Injection Device: Evidence from a Health Care Professional Opinion StudyRieke Alten, Simon Moss, Stefanie Hahne, et al.
Pageof 7